

# Alpha Synuclein - Pipeline Review, H1 2020

<https://marketpublishers.com/r/A56DAC0B2B7AEN.html>

Date: June 2020

Pages: 150

Price: US\$ 3,500.00 (Single User License)

ID: A56DAC0B2B7AEN

## Abstracts

Alpha Synuclein - Pipeline Review, H1 2020

### SUMMARY

According to the recently published report 'Alpha Synuclein – Pipeline Review, H1 2020'; Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 57 molecules. Out of which approximately 47 molecules are developed by companies and remaining by the universities/institutes.

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) – Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson's. In Parkinson's it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.

The report 'Alpha Synuclein – Pipeline Review, H1 2020' outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects.

Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 9, 21 and 13 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 9 and 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Cardiovascular, Gastrointestinal, Genetic Disorders, Infectious Disease and Ophthalmology which include indications Parkinson's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Neurodegenerative Diseases, Alzheimer's Disease, Lewy Body Dementia, Familial Amyloid Neuropathies, Amyloidosis, Constipation, Dementia, Dementia Associated With Alzheimer's Disease, Down Syndrome, Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Spinal Cord Injury, Stroke, Traumatic Brain Injury and Type 2 Diabetes.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)

The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor

projects

The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

### Introduction

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics

### Development

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Products

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Product Development Milestones

### Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indication, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..1)  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Products under Development by Companies, H1 2020 (Contd..3), H1 2020  
Number of Products under Investigation by Universities/Institutes, H1 2020  
Products under Investigation by Universities/Institutes, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by AbbVie Inc, H1 2020  
Pipeline by ABL Bio Inc, H1 2020  
Pipeline by AC Immune SA, H1 2020  
Pipeline by AFFiRiS AG, H1 2020  
Pipeline by Annovis Bio Inc, H1 2020  
Pipeline by Aprinoia Therapeutics Inc, H1 2020  
Pipeline by Arvinas Inc, H1 2020  
Pipeline by AstraZeneca Plc, H1 2020  
Pipeline by Biogen Inc, H1 2020  
Pipeline by Capo Therapeutics Inc, H1 2020  
Pipeline by Declion Pharmaceuticals Inc, H1 2020  
Pipeline by DegenRx BV, H1 2020  
Pipeline by Denali Therapeutics Inc, H1 2020  
Pipeline by Enterin Inc, H1 2020  
Pipeline by Fulcrum Therapeutics Inc, H1 2020  
Pipeline by Genmab AS, H1 2020  
Pipeline by ICB International Inc, H1 2020  
Pipeline by NeuBase Therapeutics Inc, H1 2020  
Pipeline by Neurimmune Holding AG, H1 2020  
Pipeline by Neuropore Therapies Inc, H1 2020  
Pipeline by nLife Therapeutics SL, H1 2020

Pipeline by Prevail Therapeutics Inc, H1 2020  
Pipeline by Priavoid GmbH, H1 2020  
Pipeline by Primary Peptides Inc, H1 2020  
Pipeline by Proclara Biosciences Inc, H1 2020  
Pipeline by ProMIS Neurosciences Inc, H1 2020  
Pipeline by Prothena Corp Plc, H1 2020  
Pipeline by Seelos Therapeutics, Inc., H1 2020  
Pipeline by Treventis Corp, H1 2020  
Pipeline by UCB SA, H1 2020  
Pipeline by United Neuroscience Ltd, H1 2020  
Pipeline by Voyager Therapeutics Inc, H1 2020  
Dormant Products, H1 2020  
Dormant Products, H1 2020 (Contd..1), H1 2020  
Dormant Products, H1 2020 (Contd..2), H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

AbbVie Inc

ABL Bio Inc

AC Immune SA

AFFiRiS AG

Annovis Bio Inc

Aprinoia Therapeutics Inc

Arvinas Inc

AstraZeneca Plc

Biogen Inc

Capo Therapeutics Inc

Declion Pharmaceuticals Inc

DegenRx BV

Denali Therapeutics Inc

Enterin Inc

Fulcrum Therapeutics Inc

Genmab AS

ICB International Inc

NeuBase Therapeutics Inc

Neurimmune Holding AG

Neuropore Therapies Inc

nLife Therapeutics SL

Prevail Therapeutics Inc

Priavoid GmbH

Primary Peptides Inc



Proclara Biosciences Inc  
ProMIS Neurosciences Inc  
Prothena Corp Plc  
Seelos Therapeutics, Inc.  
Treventis Corp  
UCB SA  
United Neuroscience Ltd  
Voyager Therapeutics Inc

## I would like to order

Product name: Alpha Synuclein - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/A56DAC0B2B7AEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A56DAC0B2B7AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970